Genome-Wide Association Study of Varenicline-Aided Smoking Cessation.

ABSTRACT:

Introduction

Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date, no genome-wide association studies of varenicline response have been published.

Methods

In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes. We defined short-term varenicline effectiveness (SVE) and long-term varenicline effectiveness (LVE) by assessing smoking status at 3 and 12 months, respectively, after initiating varenicline treatment. In Stage 1, comprising five European cohort studies, we tested genome-wid

SUBMITTER: Coley K 

PROVIDER: S-EPMC12453674 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature